Rosetta Genomics Ltd. ROSG announces the launch of
a molecular test for BRAF mutation analysis to help personalize therapy
for melanoma and colon cancer patients. This newest assay will
complement its broad offerings so that oncologists can optimize
treatment decisions for their cancer patients.
Rosetta Genomics' BRAF mutation analysis test utilizes highly specific
and sensitive Competitive Allele-Specific TaqMan® (CAST) PCR™ technology
that can detect as little as 0.5% mutated DNA in a large, normal DNA
sample. BRAF mutations occur in up to 50% of malignant melanomas, and
several FDA-approved BRAF inhibitor therapies have been introduced to
the market for use
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in